Medical devices, healthcare technology and the business of care
510(k) clearance · K260608

TagBand Manual; TagBand Auto

UK Innovations, GP, Ltd. · Decision date Nov 6, 2026

MEDTECHLEDGER EXPLANATIONK260608

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K260608, covering TagBand Manual and TagBand Auto, submitted by UK Innovations, GP, Ltd. The listing carries a decision date of 2026-11-06 and appears in the 510(k) final decisions rendered since October 01, 2026. In 510(k) terms, substantially equivalent means the submission was cleared to market; it is not a PMA approval.

The source record identifies the specialty as Cardiovascular and the product code as DXC, but it does not describe the device's components, materials, intended use, or any specific change from a predicate device. The relationship to any predicate is likewise unstated. Researchers should treat the clearance scope as unknown beyond the listed device names and applicant, and consult the underlying FDA 510(k) record for indications and technical detail.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Nov 6, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260608
Regulatory pathway
510(k) premarket notification
Product code
DXC
Decision code
SESE
Decision date
Nov 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Clamp, Vascular.

Product code
DXC
FDA device class
2

FDA decision timeline

  1. K260608 received

    Application receipt date recorded by FDA.

  2. K260608 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

UK Innovations, GP, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
London

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records